LRHT (Loco-Regional Hypothermia), Oncothermia, or electro-hyperthermia was developed about 20 years ago in Germany. Though it is used in many institutions and 15 countries throughout the world, only 6 clinics in Canada have a Class III licensed LRHT device.Hyperthermia is a promising approach and deserves consideration as part of standard treatment in tumour sites.
When used as a complementary treatment, it has been shown to give patients a higher quality of life and longer life expectancy as well. The treatment increases blood and oxygen flow to the area which increases the efficacy of both chemotherapy and radiation therapy respectively.
LRHT treatment is based on two key effects: cellular-level selection and energy absorption induced heating.In oncology,â€˜hyperthermiaâ€™ refers to the treatment of malignant diseases by administering heat. The results from experimental studies indicate that hyperthermia is both an effective complementarytreatment toradiotherapy and chemotherapyand is also a strong sensitizer of these treatments. The aim of loco-regional hyperthermia is to achieve the optimal thermal dose in the tumour tissue. This is generally defined as a temperature elevation between 40Â° and 45Â°C. without exceeding the tolerance limits of the surrounding normal tissues.LRHT treatment is based on two key effects: cellular-level selection and energy absorption induced heating.